These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model. de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996 [TBL] [Abstract][Full Text] [Related]
24. Tetrahydro-2-furanyl-2,4(1H,3H)-pyrimidinedione derivatives as novel antibacterial compounds against Koseki Y; Kanetaka H; Tsunosaki J; Munier-Lehmann H; Aoki S Int J Mycobacteriol; 2017; 6(1):61-69. PubMed ID: 28317807 [TBL] [Abstract][Full Text] [Related]
25. Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis. Machado D; Pires D; Perdigão J; Couto I; Portugal I; Martins M; Amaral L; Anes E; Viveiros M PLoS One; 2016; 11(2):e0149326. PubMed ID: 26919135 [TBL] [Abstract][Full Text] [Related]
26. Design of high-order antibiotic combinations against M. tuberculosis by ranking and exclusion. Yilancioglu K; Cokol M Sci Rep; 2019 Aug; 9(1):11876. PubMed ID: 31417151 [TBL] [Abstract][Full Text] [Related]
27. Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis. Foo CS; Lupien A; Kienle M; Vocat A; Benjak A; Sommer R; Lamprecht DA; Steyn AJC; Pethe K; Piton J; Altmann KH; Cole ST mBio; 2018 Oct; 9(5):. PubMed ID: 30301850 [TBL] [Abstract][Full Text] [Related]
28. In vitro activity of DNF-3 against drug-resistant Mycobacterium tuberculosis. Islam MI; Han CM; Seo H; Kim S; Mahmud HA; Nam KW; Lee BE; Sadu VS; Lee KI; Song HY Int J Antimicrob Agents; 2019 Jul; 54(1):69-74. PubMed ID: 30807817 [TBL] [Abstract][Full Text] [Related]
29. Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K+ transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB)--a novel, patentable approach to limit the emergence of XDR-TB. Martins M Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):110-7. PubMed ID: 21517742 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors. Altaf M; Miller CH; Bellows DS; O'Toole R Tuberculosis (Edinb); 2010 Nov; 90(6):333-7. PubMed ID: 20933470 [TBL] [Abstract][Full Text] [Related]
31. Identification of new benzamide inhibitor against α-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations. Naz S; Farooq U; Ali S; Sarwar R; Khan S; Abagyan R J Biomol Struct Dyn; 2019 Mar; 37(4):1043-1053. PubMed ID: 29502488 [TBL] [Abstract][Full Text] [Related]
32. [Frontier of mycobacterium research--host vs. mycobacterium]. Okada M; Shirakawa T Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793 [TBL] [Abstract][Full Text] [Related]
33. In vitro activity of (-)-deoxypergularinine, on its own and in combination with anti-tubercular drugs, against resistant strains of Mycobacterium tuberculosis. Nam KW; Jang WS; Jyoti MA; Kim S; Lee BE; Song HY Phytomedicine; 2016 May; 23(5):578-82. PubMed ID: 27064017 [TBL] [Abstract][Full Text] [Related]
34. High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery. Christophe T; Ewann F; Jeon HK; Cechetto J; Brodin P Future Med Chem; 2010 Aug; 2(8):1283-93. PubMed ID: 21426019 [TBL] [Abstract][Full Text] [Related]
35. Bis-biguanide dihydrochloride inhibits intracellular replication of M. tuberculosis and controls infection in mice. Shen H; Wang F; Zeng G; Shen L; Cheng H; Huang D; Wang R; Rong L; Chen ZW Sci Rep; 2016 Sep; 6():32725. PubMed ID: 27601302 [TBL] [Abstract][Full Text] [Related]
36. Identification of TB-E12 as a novel FtsZ inhibitor with anti-tuberculosis activity. Lin Y; Zhang H; Zhu N; Wang X; Han Y; Chen M; Jiang J; Si S Tuberculosis (Edinb); 2018 May; 110():79-85. PubMed ID: 29779778 [TBL] [Abstract][Full Text] [Related]
37. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening. Manjunatha UH; Smith PW Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708 [TBL] [Abstract][Full Text] [Related]
38. In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates. Zhang Z; Li T; Qu G; Pang Y; Zhao Y Int J Antimicrob Agents; 2015 Jan; 45(1):71-5. PubMed ID: 25459737 [TBL] [Abstract][Full Text] [Related]
39. Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase. Palencia A; Li X; Bu W; Choi W; Ding CZ; Easom EE; Feng L; Hernandez V; Houston P; Liu L; Meewan M; Mohan M; Rock FL; Sexton H; Zhang S; Zhou Y; Wan B; Wang Y; Franzblau SG; Woolhiser L; Gruppo V; Lenaerts AJ; O'Malley T; Parish T; Cooper CB; Waters MG; Ma Z; Ioerger TR; Sacchettini JC; Rullas J; Angulo-Barturen I; Pérez-Herrán E; Mendoza A; Barros D; Cusack S; Plattner JJ; Alley MR Antimicrob Agents Chemother; 2016 Oct; 60(10):6271-80. PubMed ID: 27503647 [TBL] [Abstract][Full Text] [Related]